Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation

Metabolic Syndrome Clinical Trial

Official title:

Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02219906
• Other study ID #: 130996
• Status: Completed
• Phase: N/A
• Start date: May 2014
• Est. completion date: April 7, 2019

Study information

• Verified date: April 2019
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metabolic syndrome is a group of risk factors that increase a patient's likelihood for heart attack, stroke and diabetes. Our research is aimed at understanding whether a drug, resveratrol, commonly found in grapes and red wine, would have any benefit in reducing risk factors in patients that have metabolic syndrome. Despite the use of aspirin and cholesterol reducing medications, patients with metabolic syndrome still often have sticky platelets and dysfunctional lipid profile. This is likely due to inflammation and high oxidative state. In animal studies, this drug has reduced platelet stickiness and reduced oxidative stress. However, the effects of this drug have not been researched in patients with metabolic syndrome.

We are interested in studying whether the benefits of resveratrol described in animal models can be translated to patients with metabolic syndrome who display high markers of oxidative stress. We plan to give a short intervention of drug to patients and then determine if the drug successfully:

1. Decreases the stickiness of platelets. This is important because sticky platelets are more likely to form clot and contribute to plaque formation.

2. Reduce the circulating dysfunctional HDL. HDL and its protein and lipid constituents help to inhibit oxidation, inflammation, activation of the blood vessel wall, coagulation, and platelet aggregation. Dysfunctional HDL, as occurs in metabolic syndrome patients, cannot properly protect against atherosclerosis.

Description:

Patients with metabolic syndrome are at increased risk of thrombotic complications, including myocardial infarction and cardiovascular death. A meta-analysis of the studies assessing cardiovascular risk in metabolic syndrome found a pooled relative risk for incident cardiovascular events and death of 1.78. This propensity for thrombotic vascular events is in the context of an increasing prevalence of metabolic syndrome, which in the 2003-2006 NHANES Survey was found in 34% of the US population over the age of 20.

Two important contributors to the development of myocardial infarction and stroke are lipid rich atheromatous plaques and concomitant platelet aggregation in response to the fissuring of these plaques. A growing body of evidence implicates oxidative modification of lipoprotein lipids and apolipoproteins in the genesis of plaques. Platelet hyperactivity and the variable response to antiplatelet therapy are features of the metabolic syndrome. Oxidative modifications of LDL enhance activation of platelets, which themselves are oxidatively stressed. Myeloperoxidase (MPO) initiates lipid peroxidation leading to dysfunctional HDL production. Therefore, the hypotheses for the proposed investigations will address the effects of resveratrol on platelet hyperactivity and HDL protein modifications in patients with metabolic syndrome. Resveratrol, as predicted from its structure, is an electron rich molecule that can reduce free radicals. It has distinctive actions, however, that differ from compounds that are conventionally referred to as "anti-oxidants". It has particular potency as an inhibitor of radical formation by a number of peroxidases that likely participate in the pathophysiology of metabolic syndrome. These include MPO, the peroxidase site of prostaglandin H synthase-1 (PGHS-1; cyclooxygenase-1(COX-1)) and cytochrome c.

We will test the hypothesis that:

1. resveratrol reduces platelet activation in patients with metabolic syndrome. and

2. that resveratrol reduces the oxidative modification of HDL proteins in patients with metabolic syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: April 7, 2019
• Est. primary completion date: February 7, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Metabolic Syndrome

Exclusion Criteria:

• Evidence of coronary artery disease

• Indication for use of aspirin for secondary prevention of thrombotic events

• Use of non-steroidal anti-inflammatory drugs or anti-platelet agents

• Pregnancy

• Patients with history of bleeding or gastrointestinal ulcers

• Patients with major illnesses such as ongoing malignancies, infections, cirrhosis

Related Conditions & MeSH terms

• Metabolic Syndrome
• Syndrome

Intervention

Dietary Supplement:
• Resveratrol
1000mg tid
• Placebo
1000mg tid placebo

Locations

Country	Name	City	State
United States	Baylor University	Houston	Texas
United States	Vanderbilt University	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in parameters of platelet activation	Measure platelet-monocyte aggregates by flow cytometry	baseline, 3 weeks after intervention
Primary	Change in parameter for platelet oxidative stress	Measure malondialdehyde adducts of platelet proteins	Baseline, 3 weeks after intervention
Primary	Change in parameter for platelet oxidation levels	Measure superoxide production by platelets	Baseline, 3 week after intervention
Primary	Serum Thromboxane measurments	Measure thromboxane to assess inflammation	Baseline, 3 weeks after intervention
Secondary	Change in oxidative modifications of HDL	Measure change in malondialdehyde adducts in HDL proteins	baseline, three weeks after intervention
Secondary	Change in plasma oxidative stress	Measure change in plasma isoprostanes	baselines, three weeks after intervention